Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | GLS | O94925 | 1/20 | 0.30 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567446 | 0.90 | ALOX5 (0.47) | ALOX5ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL3576818 | 0.86 | ALOX5 (0.53) | ALOX5ALDH1A1USP2TSHRHSD17B10 | |
| SCHEMBL3569286 | 0.85 | ALOX5 (0.64) | ALOX5LMNA | |
| SCHEMBL3569766 | 0.84 | ALOX5 (0.49) | ALOX5ALDH1A1TSHRLMNA | |
| SCHEMBL3568845 | 0.80 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL3568843 | 0.80 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL3571404 | 0.80 | ALOX5 (0.43) | ALOX5KMT2A | |
| SCHEMBL3573994 | 0.79 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL3573996 | 0.79 | ALOX5 (0.47) | ALOX5 | |
| SCHEMBL3569359 | 0.76 | ALOX5 (0.40) | ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7674811-B2 | 5-lipoxygenase inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2010-03-09 | — | — | US | disclosed |
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2008-01-24 | — | — | US | disclosed |
| EP-1834953-A1 | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors | Ranbaxy Laboratories Limited (IN) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021080-A1 | 5-LIPOXYGENASE INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5 1/4885ALDH1A1 210/4885RIPK1 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.